What is APUS stock price today?

APUS (Apimeds Pharmaceuticals Us Inc) stock is trading at $1.88 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is APUS stock going up or down today?

APUS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy APUS stock now?

The decision to buy APUS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is APUS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for APUS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is APUS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if APUS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is APUS's P/E ratio?

P/E ratio data for APUS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is APUS's market cap?

APUS (Apimeds Pharmaceuticals Us Inc) has a market capitalization of $0.02 billion, making it a small-cap stock.

What is APUS's price to book ratio?

APUS trades at a price-to-book (P/B) ratio of 2.90, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does APUS pay dividends?

APUS does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is APUS's dividend yield?

APUS does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is APUS stock a good long-term investment?

APUS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is APUS's revenue growth rate?

Revenue growth data for APUS is available on our dashboard with detailed financial statement analysis.

Profitability metrics for APUS are available on our dashboard with complete income statement analysis.

What are the risks of investing in APUS?

Key risks for APUS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does APUS compare to its competitors?

Compare APUS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize APUS's performance and positioning.

What is APUS's stock price target for 2026?

Our AI model provides price targets for APUS based on fundamental analysis: Bull case $2.44 (+30%), Base case $2.16 (+15%), Bear case $1.69 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about APUS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for APUS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is APUS's next earnings report?

APUS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

APUS - Apimeds Pharmaceuticals Us Inc

NYSE * Health Care * Pharmaceuticals

$1.88

+$0.00 (+0.00%)

About Apimeds Pharmaceuticals Us Inc

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company is based in Ras al-Khaimah, the United Arab Emirates. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

APUS Key Statistics

Market Cap

$23.64M

P/B Ratio

2.90

EPS

$-0.41

Employees

How APUS Compares to Peers

APUS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 1

Margin Rank

N/A

of 1

Growth Rank

N/A

of 1

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
APUS(This stock)	$23.64M	N/A	0%	0.0%	-
AMZNAmazon Com	$2.69T	34.8	0%	0.1%	vs AMZN

Apimeds Pharmaceuticals Us Inc Company Information

Headquarters: New Jersey; U.S.A
Website: www.mindwavedao.com
Sector: Health Care
Industry: Pharmaceuticals

Data Updated: April 18, 2026 at 5:24 PM EDT

Ready to invest in APUS?

Commission-free trading available. Affiliate links.

APUS Lician Score

5% confidence

4.0/10

Neutral

APUS has a Lician Score of 4/10 (Average). Areas of concern: Growth.

value

5.0

growth

2.0

quality

5.0

momentum

5.0

safety

5.0

The Lician Score is a comprehensive 1-10 rating that evaluates APUSacross five key dimensions: Value (valuation relative to sector),Growth (revenue and earnings trajectory),Quality (profitability and balance sheet strength),Momentum (price trends and analyst sentiment), andSafety (volatility and risk metrics).

APUS Financial Snowflake

5-axis analysis across key investment dimensions

4.4/10

Neutral

5.0

Value

Valuation vs. sector peers

2.0

Growth

Revenue & earnings trajectory

5.0

Quality

Profitability & moat strength

5.0

Momentum

Price trends & analyst sentiment

5.0

Safety

Financial stability & risk

Upcoming Events for APUS

Dashboard

Enter a ticker to analyze